Target: The U.S. Food and Drug Administration
Goal: Demand the unbiased consideration of prescription drugs used to treat low sexual desire in females.
The U.S Food and Drug Administration must conduct an impartial consideration of prescription drugs for treating low sexual drive in females, including the drug commonly known as the “Female Viagra” or flibanserin. With over two dozen drugs approved by the FDA regarding low sexual desire in males, similar drugs targeting low female sex drive do not appear to be subject to the same FDA standards for approval. Instead, the female-oriented libido medications may be arbitrarily subject to stricter standards.
Historically, women’s sexual dissatisfaction had been a topic shrouded by confusion and lack of discussion due to traditional societal mores. However, for the past few decades scientists have conducted medical research regarding female sexual satisfaction. The statistics alone speak volumes. One in ten women have Hypoactive Sexual Desire Disorder (HSDD), which is typically defined as a lack or low biological sex drive that causes anxiety. This disorder causes harm not just to the woman herself, but to her intimate partners, family and other valued relationships.
The FDA has approved over 24 drugs relating to curing low male sexual drive with the acknowledgement that some cause unfavorable side effects. However, the FDA has repeatedly failed to approve drugs aimed at alleviating symptoms of low female sex drive over concerns that these drugs cause side effects. This disapproval may stem from implicit bias against woman. Studies have shown that implicit gender bias by doctors and health professionals routinely lead to women’s complaints of physical ailments being treated as a psychological problem instead of a physical issue and that consequently prescription drugs will not be effective.
By signing the petition below you will help urge the Federal Food and Drug Administration to ensure that female libido drugs are fairly and appropriately considered by the agency for approval in a gender-neutral fashion.
Dear U.S. Food and Drug Administration,
Prescription drugs used to treat low female drive require timely approval by your agency. As you well know, the FDA has failed to approve these drugs due to possible side effects despite approving over 24 drugs used to treat male sexual dysfunction which also include potentially harmful side effects.
Given that medical research history definitively demonstrates that an implicit gender bias exists and that this bias causes medical professionals to undervalue the biological nature of women’s sources of discomfort, the FDA must take extra precautions to ensure every step of the approval process for female libido drugs is free of bias.
In previous generations, women’s sexual appetite and pleasure had been poorly understood. Luckily, modern scientific research demonstrates how low female sex drive can constitute a physical issue that can be successfully treated with medication. A healthy sex drive and sex life can boost the immune system, stave off depression, improve sleep, lower stress, decrease blood pressure and chances of stroke, and even lower the chances of developing some cancers. Given the myriad benefits, efforts to attain women’s sexual health equity must be supported.
I am urging you to take concrete actions to ensure that no gender bias is present and adversely influencing every step of the approval of female libido drugs now before the FDA.
[Your Name Here]
Photo credit: Ragesoss